Media coverage
4
Media coverage
Title Ophirex Publishes Phase 2 Data in BMJ Global Health from the First Use of Varespladib to Treat Venomous Snakebite Victims Media name/outlet Business Wire Country/Territory United States Date 23/10/24 URL www.businesswire.com/news/home/20241023475178/en/Ophirex-Publishes-Phase-2-Data-in-BMJ-Global-Health-from-the-First-Use-of-Varespladib-to-Treat-Venomous-Snakebite-Victims/?feedref=JjAwJuNHiystnCoBq_hl-fqXyBvmekC3Xq1G1wQ7hjMFbZM1ntlKeK-8bUzJqFSVSfe41V1BKA-b6v2ZVrSSNs-dUYKiDvY7XniNSqv88QcY1Ge_vf9QIMZ4alzIf_0HlyE0C4hZhHVlTvKnn0d0vQ== Persons Charles Gerardo Title Ophirex Publishes Phase 2 Data in BMJ Global Health from the First Use of Varespladib to Treat Venomous Snakebite Victims; Efficacy signal observed in subgroup of victims treated within five hours of bite reinforces critical importance of timely treatment Media name/outlet Business Wire Country/Territory United States Date 23/10/24 Persons Charles Gerardo Title Ophirex Publishes Phase 2 Data in BMJ Global Health from the First Use of Varespladib to Treat Venomous Snakebite Victims Media name/outlet APNews.com Country/Territory United States Date 23/10/24 URL https://apnews.com/press-release/business-wire/clinical-trials-medication-38636b29309142c8814de4195dae4b89 Persons Charles Gerardo Title Ophirex Publishes Phase 2 Data in BMJ Global Health from the First Use of Varespladib to Treat Venomous Snakebite Victims Media name/outlet Le Lezard.com Country/Territory Canada Date 23/10/24 URL https://www.lelezard.com/en/news-21574427.html Persons Charles Gerardo